Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide vs lenalidomide maintenance after autologous stem cell transplant in newly diagnosed multiple myeloma
ChiCTR2600117745Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of iberdomide in multiple myeloma (MM) (6 arms), sponsored by Peking University People's Hospital. Primary endpoint: progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600117745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117745.